Skip to main content

Advertisement

Table 4 IL28B and IL10R −1087 genotype combinations in the different study groups

From: IL28B and IL10R −1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort

  IL28B genotype
  CC CC T allele T allele
IL10R genotype HCV n = 664 GG 61 (9.2%) OR:0.322 (0.186-0.556) 148 (22.3%) 0.728 (0.446-1.188)
A allele 107 (16.1%) p < 0.001 348 (52.4%) p = 0.202
Controls n = 92 GG 22 (23.9%) OR:0.515 (0.311-0.852) 26 (28.3%) OR:4.231 (2.497-7.169)
A allele 25 (27.2%) p = 0.009 19 (20.7%) p < 0.001
SVR n = 178 GG 22 (12.4%) OR:1.648 (0.837-3.247) 37 (20.8%) OR:0.803 (0.496-1.301)
A allele 38 (21.3%) p = 0.146 81 (45.6%) p = 0.372
Non-responders n = 203 GG 16 (7.9%) OR: 1.848 (1.070-3.190) 50 (24.6%) OR:0.692 (0.462-1.037)
   A allele 26 (12.8%) p = 0.026 (54.7%)111 p = 0.074
  1. Prevalence of IL28B CC plus IL10R GG in HCV patients vs. controls OR: 0.322.
  2. IL28B CC plus IL10R A allele OR: 0.515.
  3. IL28B T allele plus IL10R A allele OR: 4.231.
  4. Prevalence of IL28B CC plus IL10R A allele in pts with SVR vs. non-responders OR:1.848.